In vitro cytotoxicity of antimicrobial conjugated electrolytes: interactions with mammalian cells

Kristin N Wilde1, David G Whitten, Heather E Canavan

  • 1Center for Biomedical Engineering, Department of Chemical and Nuclear Engineering, MSC01-1141, University of New Mexico , Albuquerque, New Mexico 87131, United States.

Insights

Conjugated phenylene ethynylene (CPE) compounds show antimicrobial properties. Longer-chained CPEs are less toxic to mammalian cells, widening their potential applications against infections like MRSA.

Area of Science:

  • Polymer Chemistry
  • Materials Science
  • Toxicology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) causes significant mortality and healthcare costs.
  • Conjugated phenylene ethynylene (CPE)-based polymers and oligomers show antimicrobial activity.
  • Mammalian cell cytotoxicity of CPEs was previously unknown, limiting their therapeutic applications.

Purpose of the Study:

  • To evaluate the cytotoxicity of various CPEs against mammalian cells.
  • To determine how factors like compound structure and light exposure affect CPE toxicity.
  • To identify CPEs with a favorable toxicity profile for potential antimicrobial applications.

Main Methods:

  • Cytotoxicity assays were performed on two mammalian cell types.
  • Eight CPEs (two polymers, six oligomers) were tested at concentrations from 1-100 ug/mL for 24 hours.
  • Cellular viability was assessed to determine toxicity levels.

Main Results:

  • Cellular viability was primarily dependent on CPE concentration.
  • Light exposure significantly impacted the toxicity of light-activated CPEs at intermediate concentrations (5-10 ug/mL).
  • Longer-chained CPEs exhibited lower cytotoxicity, allowing for a broader range of effective concentrations.

Conclusions:

  • CPE concentration is a key factor in determining mammalian cell toxicity.
  • Light-activated CPEs require careful concentration management, especially at intermediate levels.
  • Longer-chained CPEs present a promising therapeutic window for developing novel antimicrobial agents against MRSA and other resistant bacteria.